bluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor Events

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.

To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 9768329.

In addition, members of the management team will participate in the following upcoming investor conferences:

• BofA Securities 2024 Health Care Conference, Thursday, May 16, at 10:00 a.m. PT (1:00 p.m. ET) in Las Vegas, NV
• Goldman Sachs 45^th Annual Global Healthcare Conference, Wednesday, June 12, at 11:20 a.m. ET in Miami Beach, FL

To access the live webcasts of bluebird bio’s first quarter results conference call and fireside chats, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the events.

About bluebird bio, Inc.

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240506060424/en/